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In-body Network Biomedical Applications:
from Modeling to Experimentation
Valeria Loscrı́ Member, IEEE, Ladislau Matekovits Senior Member, IEEE, Ildiko Peter, and Anna Maria Vegni
Member, IEEE
Abstract—Innovative diagnostic approaches and therapies
are more and more based on the use of injections or oral
delivery of nanoparticle sized substances. For a better un-
derstanding of the overall phenomena, aiming to facilitate a
safe application at large scale, the development of accurate
models and analysis techniques are required. These techniques
take into consideration different aspects of the overall process:
accurate numerical modeling of the different phases of the
nanoparticles in the body, and knowledge of the local environ-
ment, that can be varying very fast within a short-range in
the body itself. Such aspects should be taken into account to
correctly predict the amount of drug and its timely release
for the specific disease. Deep and accurate analysis of the
interaction between the nanoparticles and the biological fluid
where the nanoparticles are immersed is mandatory for an
efficient correlation of all these aspects.
Because of their biocompatibility, in this paper, we focus
our attention on systems of Titanium (Ti), and its oxide (e.g.,
TiO2), given their specific features in terms of density, lack
of cytotoxic effects, etc. Specifically, we present the study
and design of an in-body system by characterizing each
of the emission, diffusion, and reception processes with a
proper realistic model. The theoretical investigation is further
supported by experimental study of the morphology and other
important characteristics (e.g., the pH of the particles, and
thermal stability) of TiO2 systems when immersed in a Ringer
solution, in order to derive important information related to
their potential toxicity inside the human body.
Keywords—Nanomedicine, TiO2 particles, THz band channel
capacity
I. INTRODUCTION
Nanotechnology is a challenging new research area that
finds applications in several areas of modern life i.e., from
biomedical to military, and from environmental to the in-
dustrial fields. For instance, in nanomedicine, the use of
nanodevices (i.e. nanorobots and nanosensors, opportunely
functionalized with medicament) are intended to both di-
agnostic and therapeutic purposes [1]–[3] by enhancing
their effectiveness, as well as increasing their tolerability
in the body by interfering at a minimum level with the
immune system [4]. Novel nanomedicine applications arise
to the term “theragnostics”, which is intended as a treatment
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strategy combining therapeutics with diagnostics. Basically,
theragnostics includes a wide range of areas, including
personalized medicine, and pharmacogenomics, in order to
develop efficient new targeted therapies.
Different types of nanoparticles can be exploited for nano-
medicine applications, such as gold and silver nanoparticles,
titanium dioxide TiO2 nanoparticles, dendrimers, Carbon
Nano-Tubes (CNTs), etc. [5]. The use of nanoparticles for
biomedical and sensing applications is mainly as carriers
for localized Drug Delivery Systems (DDSs) [6]–[8]. The
aim is to provide a controlled drug concentration in a given
location, where the medication is needed [1]. Alternatively,
in the case of diagnosis, the aim is to provide information
about in-body conditions, by opportunistically measuring
specific parameters and/or chemical concentrations, etc. [2]
altering as less as possible the local environment. Particu-
larly, colloidal silver has been used as an antibacterial agent
by weakening DNA replication and inactivating proteins,
while the low toxicity in biological systems of gold does
not allow its efficient use for antibiotic therapy [9]. In [10],
the authors use gold nanoparticles for diagnostic and drug
delivery applications by exploiting chitosan, with the dual
purpose of (i) acting as a reducing agent in the synthesis of
gold nanoparticles, and also (ii) promoting the penetration
and uptaking the peptide hormone insulin across the mucosa.
The use of TiO2, SiO2 and TiO2/SiO2 obtained by differ-
ent analytical techniques, and in different arrangements, is
presented in [11]–[14] for controlled delivery of drugs for
therapeutic purpose. The authors highlight also the positive
effect of such particles, since they act against bacterial
infection too and facilitate the osteoblast cell adhesion and
growth. Additionally, particles with high surface area, large
pore volume and proper pore size are important to guarantee
an excellent adsorption capacity in the therapeutic system.
In the context of body area networks [15], nanoparticulate
DDSs are therapeutic methods that use nanoparticles to
achieve diagnostic effects at the exact time, drug concen-
tration level, and location in the body, while minimizing
the effects on other healthy locations. In both DDS and
diagnostic applications, common methods adopted include
inhalation, intravenous and intramuscular injection, as well
as ingestion [16]. In all these methods, the most important
thing is to characterize the interaction between the in-body
solution and the specific nanoparticles.
The Molecular Communication (MC) [17]–[19] paradigm
allows the analysis of a nanoparticulate DDS from the
information theory perspective, as a tool to study nanoscale
biological and medical systems [20], [21]. In [21] the phar-
macokinetics of a DDS is analytically modeled through the
abstraction of MC paradigm. The authors consider physic-
ochemical processes in the particle propagation, such as (i)
the advection process i.e., the transport of particles due to the
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blood velocity, (ii) the diffusion process i.e., the Brownian
motion of particles, (iii) the absorption process i.e., the
particle absorption through tissues surrounding the blood
vessels, (iv) the reaction process i.e., the reaction between
the particles and the blood, and (v) the adhesion process i.e.,
when biomolecules bind to the drug-loaded particles. Finally,
in [22], Chahibi and Akyildiz model a drug delivery system
affected by noise effects in the nanoparticulate scenario of
the cardiovascular system.
In this paper, we refer to the MC paradigm in order
to analyze main features of a DDS, where nanoparticles
are emitted, diffuse and then are captured (received) in a
biological fluid. The DDS can be modeled as an end-to-
end system, where the nanoparticle emission process can
be assumed as a transmitted message, and the received
message is the nanoparticle reception process. Furthermore,
in order to provide completeness to the paper, we carry
out experimental results on TiO2 nanoparticles flow, which
has been immersed into a biological fluid. As it can be
noticed, in this paper a multi-disciplinary approach has been
followed for the DDS modeling. Specifically, we refer to our
previous work [23], where a nanoparticulate system has been
modeled through pharmacokinetics laws, and provide a more
accurate end-to-end DDS model, together with extensive
experimental results.
The contribution of this paper is twofold. First, we
model a drug delivery system for nanomedicine applica-
tions, through the characterization of nanoparticles emis-
sion, diffusion, and reception processes, that are analyzed
from the information theory perspective. We assume that
a nanoparticle flow is introduced within a biological fluid,
and it is free to diffuse until reaching a given position. The
model linking the nanoparticle emission and reception is
investigated as an end-to-end system, where the capacity is
derived analytically in case of ideal, and non-ideal scenarios.
Finally, we carry out an experimental analysis of specific
nanoparticles (i.e., TiO2 nanoparticles) in a biologic-like
fluidic medium, in order to infer main features as pH stability
and diffraction patterns modification determined by medium-
term permanence in biological-like fluid or quantification
of the activation energy in the given conditions. Some
preliminary results of our investigations have been recently
presented in [23] that have been further enriched here. In
particular, (i) the development of the reception process and
(ii) additional experimental characterizations on the behavior
of the considered TiO2 system in a biologic-like fluidic
medium have been considered.
Notice that the choice of TiO2 particles is due to their
benefits for biomedical applications. Indeed, among other
existing systems, because of their low density, excellent
corrosion resistance, lack of cytotoxic effects, and good
mechanical properties, Ti and its compounds (i.e., TiO2)
are well established materials for biomedical applications, as
orthopedic and dental implants, cardiovascular stents, joint
replacement [24]–[28]. The use of a controlled drug delivery
of TiO2 particles could enlarge the potential applications in
biomedical fields.
This paper is organized as follows. In Section II we
present our general (and not specific to materials discussed
later in the paper) nanoparticulate drug delivery model. We
highlight the main processes that occur when a concentra-
tion of nanoparticles is introduced in what we name here
“compartment” to indicate a closed volume containing a
biological fluid. Specifically, we detail the laws characteriz-
ing the nanoparticle emission/ transmission 1, diffusion, and
reception processes, from the information theory perspective.
At the end of this section we will be able to derive the
capacity of the proposed system (both in case of ideal and
non-ideal nanoparticle reception). In Section III we describe
the details of the experiment we dealt in order to infer the
main characteristics of the interactions between the particles
and the biological fluid. Finally, conclusions are drawn at the
end of the paper.
II. CHARACTERIZATION OF THE IN-BODY PHASES
As early described in [23], our proposed nanoparticulate
model is based on pharmacokinetics laws, which provide a
mathematical basis for analyzing how the human body reacts
to the administration of “external substances” (i.e. a fluid
with a given nanoparticle concentration). Pharmacokinetics
considers the rate at which drug concentrations change in the
body, and includes the kinetics of absorption, distribution,
metabolism and excretion of a drug. Also, from [21], in
a blood network, we can suppose that a nanoparticle flow
propagates subject to the physicochemical processes such as
absorption, reaction, adhesion, diffusion, and advection.
In this paper, we rely on one compartment pharma-
cokinetics model for oral drug administration. This is an
empirical approach, where the compartment can represent
a body/organ volume, and a compartment is modeled with
a biological fluid (e.g. the Ringer solution as described in
Section III) into which a flow of nanoparticles is added by
a rapid single dose (emission process), diffuses in the body
(diffusion process), and finally reaches a given location for
therapeutic/diagnostic aim (reception process).
A. Nanoparticle emission process
When a flow of nanoparticles is injected in the biologic
fluid, the nanoparticle concentration i.e., CNP (t), increases
according to an uniform behavior in the “compartment”,
until reaching a maximum value. The analysis of this model
relies on a simple mass balance compliant with the dissolu-
tion kinetics of TiO2 nanoparticles [29] that have been used
in the experiments described in Section III.
The mass balance model that provides the nanoparticle




= kdcin − keCNP (t) , (1)
where CNP (t) is the nanoparticle concentration behavior
along time, cin is the initial nanoparticle concentration, kd
[min−1] and ke [h−1] are the first-order dissolution and
elimination rate constants, respectively.
The solution of (1) shows a faster increase in the con-
centration for higher values of dissolution constant, while
it decreases very slowly due to typical value of elimination
constant i.e., ke = ln(2)/t1/2, where t1/2 [h] is the elimina-
tion half-life, that is the time required for the concentration
of the nanoparticles to reach half of its original value (i.e.,
t1/2 = 12 h).
The behavior of nanoparticle concentration in the
compartment reflects that of a pulse-based modulation
1In this paper, the terms emission and transmission are interchanged.
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scheme [30], where a transmitter nanomachine instanta-
neously releases a pulse of molecules [31]. A detailed
description of the nanoparticle concentration behavior has
previously been analysed in [23].
In a generic blood vessel, the nanoparticle transmission
rate rTx(t) is linked to the nanoparticle delivery rate rRx(t)




rTx (τ)h (t, τ) dτ, (2)
where h(t, τ) is the time-varying impulse response of the
MC link that takes into account for physicochemical pro-
cesses. The analytical solutions of (2) can be obtained
through the Harmonic Transfer Matrix method. Due to the
fluctuations in the blood flow, the impulse response of
the system depends on the state of the blood flow (local
environment) at the time of the injection. The analytical
expression of the time-varying impulse response of a MC
link depends on (i) the apparent velocity, (ii) the effective
diffusivity, and (iii) the reaction process.
Finally, from [21] we can derive the desired nanoparticle










where K is the number of samples, and Ts is the sampling
period that satisfies the Nyquist criterion i.e., Ts < (2B)−1,
with B the bandwidth of the time-varying impulse response
of the system. Notice that the sampling period depends on
the blood velocity and the characteristic time scale of the
advection-diffusion process.
B. Nanoparticle diffusion process
The diffusion process is analysed by distinguishing two
cases i.e., (i) the ideal, and (ii) non-ideal one. In the
first scenario, the nanoparticle concentration is assumed
as homogeneous and no nanoparticle is lost during the
diffusion. On the other hand, in the non-ideal case a portion
of nanoparticles is lost and cannot reach a destination point.
As known, the reaction of the human immune system to the
presence of nanoparticles can cause nanoparticle loss and
errors in the diffusion and reception processes, respectively.
A detailed study on nanoparticle loss in a nanoparticulate
system is investigated in [32].
In an ideal case, the concentration is assumed homo-
geneous and the residence time attains a mean reference
value. Unfortunately, in a real reactor the nanoparticle fluid
spends a different time inside the reactor, depending on
specific characteristics of the compartment. The ideal case
that models the compartment can be represented through
a bioreactor. A bioreactor is a reactor that utilizes either
a living organism or one or more enzymes from a living
organism to accomplish a certain chemical transformation.
For the non-ideal case, from (1), the nanoparticle trans-
mission rate rTx(t) can be identified with the nanoparticle
concentration flux JT (x, t) at the output of the tablet i.e.,
for x = xT . The particle concentration flux JT (x, t) is
dependent on the nanoparticle concentration gradient at time
t and position x through the Fick’s first law, as follows
JT (x, t) = −D∇CNP (x, t) , (4)
where D [cm2/s] is the diffusion coefficient, assumed as a
constant value for a given fluidic medium, and depending
on the size and shape of nanoparticles, as well as the
interaction with the solvent and viscosity of the solvent.
Unfortunately, the Fick’s first law works when applied to
steady state systems, namely the concentration will keep
constant both along the space and in the time. In our
application, the concentration changes during the time, since
nanoparticles diffuse along the space determining different
levels of concentrations. For that, we need to consider
the Fick’s second law. In practice, the diffusion associated







+ b′ · CNP (x, t) , (5)
where b′ is a kinetic rate constant, and CNP is the drug
concentration as transmitted from the previous phase. Due
to the thinness of the wall as compared to the overall
compartment radius, we can use Cartesian coordinates as
approximation instead of cylindrical coordinates.
We consider our compartment with a total volume V , and
a flux F going through the two reactors. Then, we can apply
and solve the mass balances that follow directly from (5).
The mass balance on the first reactor can be modeled as a
















with the following conditions
C1(t = 0) = 0, Cinput(t) = CNP · δ(t). (7)
This leads to the solution for C1(t) as
C1(t) = CNP · e−(
k+1
τ )t, (8)
where τ = V2F . The quantity (CNP − C1(t)) corresponds to
the portion of nanoparticle concentration that will be directly
eliminated by the body, without reaching the receiver.


























which represents the concentration of dissolved nanoparti-
cles in the compartment.
As we have modeled a scenario as a fluidic medium
where nanoparticles are free to move following the diffusion
laws until reaching the target cells 2, they are able to form
chemical bonds with them. Thus, from (10), we can obtain
the concentration of bonds i.e., Cb (t), formed due to the
dissolved nanoparticles bound with the receptors, which can
be described by the following formula:







, t > δ
0, t ≤ δ
(11)
2As an instance, a target cell is a tumor cell that has been previously
detected.
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where NB is the maximum number of bonds that can
occur i.e., NB = maxC2 (t), τ [s] is the delay necessary
for the bond formation, δ [s] is the start time of the
reception process that is related to the diffusion delay of
the nanoparticles, and u(t) is the Heaviside step function.
C. Nanoparticle reception process
In the reception process, a nanoparticle is received when
it forms chemical bonds with the receptors of a target cell,
following the ligand-receptor bond phenomenon.
Not all nanoparticles can form bonds, but just those
that reached the location of a target cell. Indeed, we can
distinguish (i) a portion of nanoparticles concentration able
to reach a target cell (namely, the most resistant 3 –MR–
nanoparticles), and (ii) the remaining part comprised of those
nanoparticles that are directly eliminated by the elimination
process, without reaching any target cell (namely, the less
resistant –LR– nanoparticles) 4. Indeed, the transmitter emits
a flow of nanoparticles, which will diffuse in the medium. A
few of them will have a most resistant behavior, and will be
the dissolved nanoparticles (i.e., MR), while others will be
the eliminated nanoparticles (i.e., LR). At the receiver side,
only the MR nanoparticles will be received, while the LR
nanoparticles will be eliminated.
In the capture process, we distinguish two cases for
(i) ideal, and (ii) non-ideal channel. In the case of ideal
channel, nanoparticles are emitted by the transmitter and
are correctly bound by the receiver. This corresponds to no
diffusion errors (e.g., no nanoparticle elimination), and no
reception errors (e.g., no queuing delays at the receptors).
On the other side, for the non-ideal channel, nanoparticles
can be affected by diffusion errors (e.g., nanoparticles can
be eliminated before reaching the receiver), or are not bound
due to interfering nanoparticles (e.g., nanoparticles near the
receptors that cause cross-talk and interference). As an in-
stance, during the diffusion process, a few nanoparticles can
be damaged by obstructions and other interfering molecules
(e.g., the B-cells of the human immune system [33]), with
the consequence that those nanoparticles are eliminated by
the body before reaching target cells.
Let us model the transmitter as a discrete memory-less
source that emits nanoparticles, all potentially able to diffuse
in the volume and reach the target cells. By assuming
the channel model as a binary symmetric channel, the
transmitter is modeled as emitting a binary variable Xi with
i = [1, 2], whose values are x1 = 1, and x2 = 0, associated
to one MR, and one LR nanoparticle, respectively. Then, the
probabilities of emitting the symbols x(1,2) are
P (Xi) =
{
P (x1) = p,
P (x2) = 1− p.
(12)
The receiver can form binds only when a MR nanoparticle
arrives. Then, the receiver can receive (i) one or (ii) no
nanoparticle. The received signal can be expressed as a
binary variable Yj with j = [1, 2], whose values are y1 = 1,
and y2 = 0, respectively associated to one bond, and no
bond.
3The term “resistant” means the skill of nanoparticles to diffuse in the
biological fluid, and then reach a target cell.
4Notice that also the MR nanoparticles will be eliminated by biodegra-
dation process, after having absolved the drug delivery process.
The diffusion channel model is assumed as a binary
symmetric channel. Also, we will distinguish between the
ideal and non-ideal scenarios, respectively when the correct
reception probability is maximum, and not.
In the case of ideal channel, we can calculate the follow-
ing conditioned probabilities:
P (y1|x1) = 1, P (y1|x2) = 0, (13)
P (y2|x1) = 0, P (y2|x2) = 1, (14)
from which we can obtain the mutual information in the
ideal case (i.e., II ), as





P (xi)P (yj |xi) log
P (yj |xi)∑
i




II (Xi, Yj) = p log
1
p
+ (1− p) log 1
(1− p)
, (16)
that represents the entropy at the transmitter. Finally, from












Notice that (17) depends on the probability p of emitting
one MR nanoparticle, whose behavior is intuitively decreas-
ing when the nanoparticle concentration CNP (t) decreases
as well. The expression of p can be formulated following






where ω = 2πf [Hz], and τ [ms] is the time constant of the
RC circuit. Notice that τ has lower values corresponding
to higher probabilities of one MR emission, meaning that
slower is the slope of |p(ω)|, faster is the increase of
the nanoparticle concentration due to the emission of MR
nanoparticles.
In the time domain, the probability p results:
p (t) =
{
≥ (1− p) , for t ≤ t1,
< (1− p) , for t > t1,
(19)
where t1 is the time instant where the concentration of
nanoparticles is maximum. Eq. (19) states that for t ≤ t1
(i.e., for increasing values of CNP (t)), the probability of
emitting an MR nanoparticle is greater than (or equal to) the
probability of emitting a LR nanoparticle i.e., (1−p), while
for t > t1 i.e., for decreasing values of CNP (t), the probabil-
ity of emitting an MR nanoparticle results lower than that of
emitting a LR nanoparticle. On the other side, the probability
(1− p) of emitting a LR nanoparticle is expected to increase
when the overall nanoparticle concentration decreases, that
is for t > t1.
Still referring to the circuit theory, it follows that the
behavior of q = (1− p) can be modeled as the charge of


























τ = 3 ms
τ = 5 ms
τ = 7 ms
Fig. 1. Capacity [b/s] of an ideal channel, for different values of frequency.
Different curves correspond to different values of probability p, again








Fig. 2. Binary symmetric channel model for nanoparticle reception. A bond
is formed between a MR nanoparticle and the receptor with probability r.
Errors at the receiver can occur with probability e.
Referring back to (17), in the ideal scenario, the channel
capacity can be expressed in terms of spectral efficiency
[b/s/Hz], as shown in Fig. 1. This represents the information
rate (i.e., the amount of nanoparticles in the time unit) that
can be transmitted over a given bandwidth i.e., [1, 106] Hz.
This is true since we have considered the system as a
binary symmetric channel, when the nanoparticle emis-
sion/reception corresponds to bit emission/reception. Finally,
the frequency spectrum considered in these analytic results
ranges from 1 Hz to 1 MHz. Although the nanoparticles we
are considering show size in the nanoscale level, correspond-
ing to a frequency range in the THz band, we believe that
the results in a lower frequency range could help the future
development of nanoscale communication systems. Also, we
do not consider a wider frequency range since such results
up to 1 MHz already show clearly the trend of the spectra
efficiency as a function of the frequency, where the peak
of capacity can be easily shifted to higher frequencies. An
analogous consideration has been adopted in [34].
From Fig. 1, we observe that the three curves of
capacity are obtained for different values of probability p.
However, we notice the maximum values are the same,
i.e. C = 0.69 [b/s], independently from the probability p,
occurring for different values of frequency.
In the case of non-ideal channel, the system model can
be represented as in Fig. 2, and the following conditioned
probabilities hold:
P (y1|x1) = r, P (y1|x2) = e, (21)
P (y2|x1) = e, P (y2|x2) = r, (22)
where e = 1 − r i.e., with 0 < e < 1, and r i.e., with
0 < r < 1, are the error and correct reception probability,
respectively. This case corresponds to the ideal channel when
r = 1, and then, e = 0. Notice that the error probability e
is when one of the following events occurs:
1) The transmitter emits one MR nanoparticle (i.e.,
Xi = x1), but it is not able to be bound at the
receptor, and no bond is formed (i.e., Yi = y2);


















r = 0.2, τ = 3 ms
r = 0.4, τ = 5 ms
r = 0.6, τ = 7 ms
r = 0.8, τ = 9 ms


















r = 0.2, τ = 9 ms
r = 0.4, τ = 7 ms
r = 0.6, τ = 5 ms
r = 0.8, τ = 3 ms
(a) (b)
Fig. 3. Capacity [b/s] of a non-ideal channel (i.e., r 6= 1). Different curves
correspond to different values of probability r and τ .
2) The transmitter emits one LR nanoparticle (i.e., Xi =
x2), and the receiver notifies one bond has been
formed (i.e., Yi = y1).
The first event depends on the errors during the nanopar-
ticle diffusion process; as an instance, one MR nanoparticle
arrives at the receiver but can form no bond. On the other
side, in the second event, one bond is formed even if
the transmitter has emitted one LR nanoparticle, which is
expected to be eliminated by the body, and then should never
reach the receptor. However, it could happen that in the very
near field of the receptor, one interfering nanoparticle could
form a “fake” bond.
The expression of the mutual information for the non-ideal
channel (i.e., INI ) is
INI (Xi, Yi) = r log r + (1− r) log (1− r)+
− (1− p− r + 2rp) log (1− p− r + 2rp)+
− (p− 2rp+ r) log (p+ r − 2rp) .
(23)
Let us pose (p+ r − 2rp) = η, then (23) becomes
INI (Xi, Yi) = r log r + (1− r) log (1− r)+
−η log η − (1− η) log (1− η) . (24)
Notice that the meaning of η can be represented also as:
η = p
(
1− 2r + rp
)
= pe+ rq, (25)
where the first term pe represents the probability that one
MR nanoparticle has been transmitted and an error has been
notified at the receiver, while the term rq is the probability
that one LR nanoparticle has been transmitted and a correct
reception has occurred. Such considerations are true since
the probability of emitting one MR/LR nanoparticle is
independent on the error occurring at the receiver, but it
only depends on the channel noise and obstructions. Thus,
η represents the contributions of errors occurring in a non-
ideal channel.
Finally, from (24), we can obtain the channel capacity in
the case of non-ideal scenario as
CNI = max INI(Xi, Yi) =
= max
r,η
[r log r + (1− r) log(1− r)
−η log η − (1− η) log(1− η)].
(26)
Analogously to the case of ideal channel, the capacity still
depends on the probability p of emitting one MR nanoparti-
cle, and moreover it depends also on the probabilities r and
η.
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Fig. 4. Capacity [b/s] of a non-ideal channel for a fixed value of τ [ms]
and different values of r.
Fig. 3 depict different curves of the channel capacity 5, in
the case of non-ideal channel, for different values of r and
τ . In Fig. 3 (a), we observe high capacity for highest and
lowest values of the couple of correct reception probability r,
and time constant τ . This means that (i) for r = 0.8 and τ =
9 ms (i.e., green line) the correct reception probability is the
highest but the lowest is the probability of MR nanoparticle
emission, and (ii) for r = 0.2 and τ = 3 ms (i.e., black line)
lowest is the correct reception probability but highest is the
probability of MR nanoparticle emission. In these cases, the
capacity results highest with frequency variations, due to
different values of τ . In contrast, for the other cases (see
red and blue lines), the capacity is strongly reduced, still
with frequency shifts.
Again, Fig. 3 (b) shows similar behavior of capacity for
different values of the couple (r, τ). This states that the
magnitude of the capacity does not depends on the events
of emitting one MR or LR nanoparticle (i.e., the value of
τ ), but only on the channel behavior (i.e., the probability
of correct/wrong reception). Indeed, given a fixed value of
τ , the higher values of capacity are obtained for r → 1 for
r > 0.5, and for r → 0 for r < 0.5, while for r = 0.5 the
capacity is null. Fig. 4 depicts such a behavior of a non-ideal
channel for τ = 7 ms. The highest capacity is 0.368 [b/s]
given by r = [0.1, 0.9].
In the theoretical derivation of the emission, diffusion
and reception processes, we characterize the spatio/temporal
evolution of the nanoparticles without taking into account
specific features of the nanoparticles and the fluid properties
and interactions where they are immersed. This theoretical
evaluation needs to be supported by a practical evaluation
that allows the analysis of these features that would be taken
into account as corrective factors in the theoretical model.
In the next section we will show how to derive and evaluate
the main factors characterizing the particles and the fluid
as a whole system. The diffusion of the TiO2 particles is
associated to the activation energy of the biological system.
III. IN-BODY MODELING: EXPERIMENTAL EVALUATION
AND CHARACTERIZATION
In this section we will describe the details and features of
the particles, and the solution considered to infer the main
5The channel capacity [b/s] versus frequency represents the spectral
efficiency [b/s/Hz].
features of the interaction between particles and body-like
fluid solution. Specifically, we will study the morphology
of the particles and any pH variations of the considered
solutions. This analysis will allow the validation of the
theoretical approach as derived in the previous section.
TiO2 (anatase, powder, 99.99% purity; Sigma-Aldrich)
and an aqueous solution of chlorides of sodium, potassium
and calcium in the same concentrations as normal body flu-
ids (Ringer solution, 7.5 ml lactic acid, 5.85 g NaCl, 300 ml
H2O di grade 2 purity, and 700 ml H2O and regulation of
the pH to 6.9 − 7.0) were used for the experiments. It is
worth to notice that the particles we considered to deal our
experiments are µ − sized (i.e. 40 and 44µ m) because of
the easier treatability and analysis of these particles. This
solution is often used as a physiological solution for in
vitro study of biomaterials due to its similarity to the body
environment.
Two different TiO2 powders of dissimilar particle sizes,
namely 40 and 44 micron respectively, have been selected
for the experiments. Investigations on the metallic particles
and their influence on the physiological solution has been
carried out aiming to comprehend how these particles can
influence the interactions between the biological system and
the specific therapeutic nanostructure. In particular, struc-
tural and morphological observation by Scanning Electron
Microscopy (SEM) and X-Ray diffraction, thermal analysis
using Differential Scanning Calorimetry (DSC) and the
metal ion release evaluation by pH measurements have
been performed on the initial TiO2 particles and compared
with data associated to samples after their permanence in
simulated body fluids.
X-Ray diffraction patterns of the TiO2 powders, in the
initial condition and after their 14 days permanence in
the physiological solution are shown in Fig. 5. Both X-
Ray patterns related to the original powders show a strong
diffraction peaks at 2θ = [25◦, 48◦] indicating the presence
of the anatase phase. All peaks are in good agreement with
the standard spectrum (JCPDS no 84-1286). As reported,
the diffraction pattern peak intensity of the TiO2 increases
with increasing particles size from 40 µm to 44 µm. In
terms of crystal structure, anatase, have Ti in an octahedral
coordination with respect to the O atoms. In this crystal
structure, Ti4+ is present as TiO6 octahedra and crystallize
in a tetragonal unit cell. The development of monoclinic
Titanium Hydrogen Oxide was observed as evidenced in
Fig. 5 (dashed line ellipse), because of their permanence
in the physiological solution.
The chemical bond established between the TiO2 particles
and O and H atoms from the aqueous solution results
in an un-stable structure, making the hydrophilic powders
more reactive towards any possible chemical compound, and
suitable for drug delivery with a correct ability of controlled
release for a prolonged period.
In line with some literature data [35], [36], our DSC
study indicates that at high temperature, phase transforma-
tion process occurs, and the exothermally and irreversibly
transformation of anatase to rutile takes place, for the
starting TiO2 powder with a significant reorganization of the
structure. This transformation does not affect the considered
in-body system, since it arises at higher temperature level
that human body can be reals, as reported in the DSC
thermograms of the TiO2 particles at 44 µm, in Fig. 6
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Fig. 5. X-Ray diffraction patterns for the TiO2 powders of both sizes (i.e.,
40 and 44 micron): the initial powders, and after their permanence for 14
days in the physiological solution (labelled as “treated”).
(a), but some information can be deduced concerning the
necessary minimum energy to start a chemical reaction, or
to reach a transition state in the case of drug transport and
administration.
DSC studies were carried out to confirm the stability of
the powders in the interest temperature range for the human
body and to collect information about the TiO2 particles
diffusion velocity in the biological environment by analyzing
the activation energy of the system. The most important
factors that influence the velocity of the reaction are (i)
the nature and the concentration of the TiO2 and of the
therapeutic particles, and (ii) the temperature. Proportionally
to the increase of the reagents concentration the probability
of the collisions and the velocity of the particles increases;
higher surface contact between the particles favors higher
reaction rate, while higher temperature leads obtaining more
collisions between the particles and the velocity of the
reaction become higher.
Calculations have been performed to estimate the kinetic
parameter as activation energy and to qualitatively correlate
it to the rate of the reaction. The activation energy is very
low (i.e., Ea ∼ 11.65 kJ/mol) and, according to the metal-
lic ion release measurements, no any chemical interaction
between the TiO2 particles and the biological solution has
been obtained. The activation energy will increase when
anchoring the therapeutic particles to the TiO2 particles
before immersing them in the biological fluid. There are
ample space to the control of the reaction between TiO2
particles and the therapeutic particles in the preferred way
according to the targeted application, i.e., selection of the
proper drug and its quantity for the given treatement.
The relationship between activation energy, Ea [J mol−1],
and the velocity of a chemical reaction is provided by
Arrhenius equation i.e.,




where k is a reaction rate constant (measured in s−1 for
first order reactions), R is the universal gas constant (i.e.,
8.314472 [J K−1 mol−1]), A is the pre-exponential factor
(measured in [s−1] for first order reactions), and T is the
temperature [K]. The inverse exponential relationship be-
tween activation energy and the rate constant guarantees that
the reactions with a very high activation energy will have a
very low reaction rate. As activation energy decreases, the
reaction rate increases. The activation energy is determined
(a) (b)
Fig. 6. (a) Heat flow curves of the TiO2 particles at 44µm, obtained at
two heating rates. (b) Plot of ln(β/Tp) vs. 103/Tp for calculations of the
activation energy based on the heating rate β of the TiO2 particles.
by Kissinger’s method i.e., with no precise knowledge of



















where Tp [K] is the temperature corresponding to the max-
imum reaction rate (peak), α is the conversion at Tp, n is
the reaction order, and β is the heating rate expressed in [K
s−1]. Considering Kissinger’s approximation, it follows:
f (αmax) = n(1− αmax)n−1 ∼= const. (29)






versus 1Tp , as depicted in Fig. 6 (b).
The pH of the solutions containing the TiO2 powders was
measured at the pre-set time intervals during 14 days. The
quantity of metal ions released in the physiological solution
is negligible even after 14 days: the pH value of the solutions
remains constant. The results obtained for the pH value and
the weight loss fulfill the conditions required by the Standard
ISO 10271/2011 concerning the evaluation of the corrosion
resistance of the materials used in bio environment.
The particles shape and their surface reactivity influence
the transport properties of other particles in the human
environment, and thus affecting the adhesion kintetics of
the therapeutic particles loaded on and their transfer to the
favorite position. As illustrated in Fig. 7, the TiO2 particles
show a controlled size distribution even if not perfectly
regular as their size concerns. This aspect can be capitalized
to improve the drug transport and their delivery efficiency
as compared to the identical spherical shape particles. After
their permanence in the physiological solution, some cluster
development has been observed with increased surface area.
This configuration highlights the positive effect coming from
the permanence in the biological solution favoring the most
efficient loading of the therapeutic particles obtaining higher
attachment to the specific therapeutic particles as a vascular
barrier.
IV. CONCLUSIONS
Results of investigation on how nanoparticles behave in
the human body for nanomedicine applications have been
presented. The action is described by means of the modeling
of the emission, diffusion and reception processes, which
represent the overall end-to-end system from a transmitter




Fig. 7. SEM microstructure of TiO2 particles for different states and size
i.e., (a) initial state and 40µm size, (b) initial state and 44µm size, (c) in
solution and 40µm size, and (d) in solution and 44µm size.
oral drug administration has been presented and discussed.
From the characterization of the DDS channel we derived
the capacity both in case of ideal and non-ideal scenario.
Specifically, TiO2 particles in a biological-like fluid system
as possible carrier to sustain drugs has further been consid-
ered.
Experimental results on their medium-time presence in
biological-like fluids confirm their stability within the sys-
tem, and put in evidence their capability to be used as carrier
for drug delivery. The results of the investigation make
evident the possibility of combining the biocompatibility of
TiO2 to the drug delivery features and their use in biomedical
field. The observed complete absence of any release of Ti
ions in the physiological solution demonstrates, once again, a
non-toxic character of the considered molecule. The particles
with a high surface area show a higher tendency to be wetted
by the aqueous biological solution and they can support more
efficiently any drug loaded on their surfaces.
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